Why Some Cancer Screening Tests Find Cancers That Never Needed to Be Found

A screening test that comes back positive feels like a verdict. In reality, it's a probability, and sometimes the probability is wrong. Every screening test balances two different kinds of accuracy: how well it catches true cancers, called sensitivity, and how well it correctly clears people who don't have cancer, called specificity. No test gets both perfectly right.

When specificity is less than perfect, some healthy people will get a positive result anyway. This is a false positive, a flag raised when there is actually no cancer there. It usually leads to more tests, like biopsies or repeat imaging, and often real anxiety, before it's eventually ruled out. False positives are frustrating and sometimes physically invasive, but they are at least correctable once more testing clarifies the picture.

A Trickier Problem Than a Wrong Result

Overdiagnosis is different, and in some ways more unsettling. It isn't a mistaken result. It's a true finding of a real cancer, one that genuinely exists under the microscope, that would never have grown, spread, or caused symptoms if it had simply been left alone. The person is not wrong to have cancer. The problem is that this particular cancer was never going to matter.

Because there's no way to look at a tumor and know for certain it would have stayed harmless, overdiagnosed cancers get treated like any other. That leads to overtreatment: surgery, radiation, or other therapy given to someone who could not have benefited from it, only faced its risks. Think of it like clearing out a garden bed because you spotted a few weeds, only some of those weeds would have died on their own by next season anyway. You can't tell which ones in advance, so you pull them all.

Two Statistical Illusions That Flatter Screening

Screening programs can also look more successful than they really are because of how survival statistics behave. The first distortion is lead-time bias. If a cancer is found earlier through screening, the clock on "survival time" starts earlier too, even if the actual date of death doesn't change at all. The patient appears to survive longer purely because they were diagnosed sooner, not because they actually lived longer.

The second is length-time bias. Screening tests, especially ones done at fixed intervals, are simply better at catching slow-growing cancers than fast-growing ones. A slow tumor sits around for years, giving a scheduled screening test plenty of chances to spot it. A fast, aggressive tumor can appear and cause symptoms between screenings, slipping past the test entirely. Over time, screening programs end up disproportionately full of the slower, less dangerous cancers, which skews the statistics toward looking more effective than they truly are.

What Decades of Mammography Data Revealed

Breast cancer screening offers one of the clearest real-world illustrations of overdiagnosis. Research examining three decades of mammography screening found a pattern that should have looked different if screening were simply catching dangerous cancers earlier: a large rise in early-stage breast cancer diagnoses that was not matched by an equivalent drop in late-stage, more dangerous cancers. If screening were only finding tumors sooner, the early-stage increase should have come with a roughly matching decline in late-stage cases down the line. That didn't fully happen, suggesting many of the newly found early cancers would never have progressed to the advanced stage at all.

A related analysis led by H. Gilbert Welch and colleagues looked at tumor size trends and reached a similar conclusion: screening appears to have shifted a substantial share of diagnoses toward smaller tumors that were unlikely to ever become life-threatening, rather than meaningfully reducing the share of large, dangerous tumors. None of this means mammography has no value. It means a portion of what it finds falls into a gray zone where treatment decisions are harder to weigh, because doctors still cannot reliably tell which small, early cancers would have stayed quiet.

South Korea's Thyroid Cancer Surge

Thyroid cancer provides an even starker national-scale example. When ultrasound screening for thyroid cancer expanded rapidly in South Korea, diagnoses of thyroid cancer rose dramatically, by several-fold over a period of years. If that surge reflected a genuine wave of new, dangerous cancers, thyroid cancer deaths should have risen too, or at least fallen as more cancers were caught and treated early.

Neither happened. Thyroid cancer mortality stayed essentially flat throughout the screening boom. The pattern points to a large reservoir of small, slow-growing thyroid tumors that exist in many people without ever causing harm, tumors that ultrasound is now sensitive enough to detect. Widespread screening simply pulled large numbers of them into view, most of which were then surgically treated anyway. It stands as one of the clearest documented cases of overdiagnosis operating at a population level.

Weighing the Trade-offs

None of this means screening is a bad idea or that false positives and overdiagnosis cancel out its value. Screening has genuinely reduced deaths from some cancers, and for people at elevated risk, the balance of benefit and harm can look quite different than it does for someone at average risk. What the evidence does show is that screening is not a simple, cost-free act of early detection. It carries real statistical trade-offs that are easy to misjudge from the outside.

For patients, the practical takeaway isn't to avoid recommended screening. It's to understand that a positive result is a starting point for more information, not a final answer, and that finding more cancer is not automatically the same as saving more lives. Those are judgments best worked through with a healthcare provider who can weigh a person's individual risk, the specific test's known limitations, and what current guidelines recommend for someone in their situation.